ADC Therapeutics - רווח למניה בשנים עשר החודשים האחרונים ADCT

The 12-month net income per share chart for ADC Therapeutics (ADCT) provided by GURU.Markets confirms revenue strengthening driven by the demand for Zynlonta, with the current level sitting around -0.53. Business development relies on the success of new clinical trials and insurance coverage in the US. Since targeted blood cancer therapy is non-cyclical, market share and the medical value of products remain the primary growth drivers.
פילוחי נתונים אנליטיים מרוכזים עבור ADC Therapeutics Corp (ADCT)

This metric is calculated as the ratio of net income to the total number of shares outstanding over a rolling year, measuring the actual efficiency of capital generation per share. Analyzing the rolling earnings per share (EPS) allows for an assessment of the financial stability of ADC Therapeutics (ADCT) against the backdrop of high antibody development costs and drug toxicity risks.